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Background: Convincing evidence suggests that poorly soluble low-toxicity particles (PSP) exert two unifying major
modes of action (MoA), in which one appears to be deposition-related acute, whilst the other is retention-related and
occurs with particle accumulation in the lung and associated persistent inflammation. Either MoA has its study- and
cumulative dose-specific adverse outcome and metric. Modeling procedures were applied to better understand as to
which extent protocol variables may predetermine any specific outcome of study. The results from modeled and
empirical studies served as basis to derive OELs from modeled and empirically confirmed directions.
Results: This analysis demonstrates that the accumulated retained particle displacement volume was the most
prominent unifying denominator linking the pulmonary retained volumetric particle dose to inflammogenicity and
toxicity. However, conventional study design may not always be appropriate to unequivocally discriminate the surface
thermodynamics-related acute adversity from the cumulative retention volume-related chronic adversity. Thus, in the
absence of kinetically designed studies, it may become increasingly challenging to differentiate substance-specific
deposition-related acute effects from the more chronic retained cumulative dose-related effects.
Conclusion: It is concluded that the degree of dissolution of particles in the pulmonary environment seems to be
generally underestimated with the possibility to attribute to toxicity due to decreased particle size and associated
changes in thermodynamics and kinetics of dissolution. Accordingly, acute deposition-related outcomes become an
important secondary variable within the pulmonary microenvironment. In turn, lung-overload related chronic
adversities seem to be better described by the particle volume metric. This analysis supports the concept that
‘self-validating’, hypothesis-based computational study design delivers the highest level of unifying information required
for the risk characterization of PSP. In demonstrating that the PSP under consideration is truly following the generic
PSP-paradigm, this higher level of mechanistic information reduces the potential uncertainty involved with OEL
derivation.
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This paper focuses on the minimal prerequisites for de-
riving an occupational exposure limit value (OEL) of
materials subsumed under the hypernym “poorly soluble
low-toxicity granular particles (PSP)” at early stages of
product development with yet limited human exposure
data. At this stage, OELs have to be derived on the basis
of regulatory-driven toxicity studies in general and re-
peated inhalation toxicity studies in particular. These
animal studies are designed to reveal an undisputable
toxicological threshold dose of adversity to occur to in-
haled particles (no-adverse-effect level, NOAEL). This
enables, for instance, the derivation of a no-effect level
(DNEL) in humans or the setting of an OEL [1-3]. A
novel simulation approach was developed to predict
both NOAELs and DNELs/OELs at data lean situations
and for designing repeated inhalation studies on rats to
verify early predictions [4-6]. Direct extrapolation of the
effect levels from animals to humans, that is to use a cu-
mulative assessment factor (AF) of 1, has been suggested
[4,7]. In this regulatory context, harmonized OECD test-
ing guidelines [8-10] should be observed to design and
execute the regulatory set of studies to fulfill the sub-
stances’ requirement for Registration, Evaluation, Author-
isation of Chemicals (REACH) and Globally Harmonised
System (GHS) of Classification and Labeling [2,3,7,11]. It
is beyond the scope of this concise paper to reproduce the
specific terminology and background detailed in these
guidelines or those related to the concepts to calculate the
human equivalent concentration (HEC) [12] which served
as basis for the translation of data from rat inhalation
studies to humans.
Knowledge about the mechanisms underlying the ob-
served adverse key effect as well as the variables determin-
ing fate, either linked to the time-course changes of the
key effect and/or associated dose at the target organ level,
are basic prerequisites to define the metrics to be used for
describing any cumulative dose-effect/response relation-
ship. There is a general consensus that testing approaches
should be designed to enable and advance computational
tools with a particular emphasis on physiologically based
pharmaco(toxico)kinetic modeling (PBPK). A key to this is
linking the particle properties to both disposition/fate,
and toxic effects [13]. The approach delineated in this re-
view aimed to amalgamate effect-based “associative pul-
monary particokinetics” with the conventional mass-based
kinetics of deposited and retained particles in the lung.
Pursuant to these paradigms, toxicity testing strategies for
PSP should be designed and executed in a manner in
which the incremental intermittent dosing and recovery
periods match the kinetics of accumulation and clearance
at the portal of entry and site of manifestation of toxicity.
In following a hypothesis-based paradigm in study design,
adversities related to any generic ‘kinetic lung overload’and/or particle-specific toxicities can readily be identified
as detailed elsewhere [4]. The novelty of the model con-
structed is the focus to interrelate the kinetic changes
within the pool of phagocytes relative to the changed
retained PSP volume. Past approaches addressing this
issue focused on the alveolar mobility kinetics in relation
to cellular PSP overload to better understand high-dose
outcomes of long-term inhalation studies [14-21]. In this
context, the term ‘displacement volume’ was used to de-
fine the volume of assembled structures consumed within
the pool of alveolar phagocytes. Accordingly, the apparent
density (ρ) of the assembled structure of PSP becomes an
important critical qualifier of overload-dependent pul-
monary toxicity. The basic hypothesis of the novel ap-
proach described in this paper defines any increase in the
basal pool size of phagocytes above 6% to be the first step
into adversity. The validation of this approach was shown
to be simple and straightforward, namely increase in total
cell counts retrieved in bronchoalveolar lavage (BAL) is
taken as evidence to have attained the transition from
homeostasis to adversity [4-6,22].
The uncertainty involved in the translational process of
extrapolation and adjustment of findings from regulatory-
compliant repeated exposure inhalation bioassays on rats
to workplace exposures can be reduced when predicting
and verifying that level of cumulative dose that prevents
adversity to occur in the lung [4]. Suffice it to say, a PSP
deposited and retained at the alveolar level may initiate
some homeostatic change, e.g., attraction of phagocytes
for particle removal. PBPK-modeling is conducive the bet-
ter discriminate adversities originating from kinetic pro-
cesses, e.g., kinetic particle overload, or from intrinsic
particle toxicity. When adjusting the dosimetric variables
typical of healthy workers, the dosimetrically adjusted
human-equivalent daily exposure dose (OEL) can readily
be estimated by following the principles of the HEC ap-
proach [4,5,12].
Regulatory toxicology is involved with the charac-
terization of a ‘key event’ as an important aspect of tox-
icity leading to many final endpoints. This paper focuses
on dosimetric issues of the key Mode of Action (MoA)
resulting in kinetic lung overload. This ‘key event’ is de-
fined as the first etiopathologic manifestation from the
transition of homeostasis towards adversity and seems
to be indicated best by an early increase of the pool-size
of alveolar phagocytes (macrophages, AM) and neu-
trophilic granulocytes (PMN). These endpoints can be
modeled assuming that 6% of the AM-volume can be
consumed by PSPs without changes in pathways causing
an increased recruitment of phagocytes or inflammatory
cells, i.e., processes that precede additional adversities
(for details see [15]). The validity of modeled outcomes
with focus on the degree of overload-related increased
pool-size of phagocytes and proportionally decreased
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empirical data [4,6,23] and served as cornerstone to sup-
port the approach taken. The adversities occurring be-
yond this overload-threshold may follow multiple and
complex cumulative-dose-dependent Adverse Outcome
Pathways (AOP). Such an AOP is a conceptual construct
that portrays existing knowledge concerning the pathway
of causal linkages between a molecular initiating event
and a final adverse effect at a biological level of orga-
nization that was proposed as relevant for regulatory
decisions [24]. The adverse effect occurring with PSP re-
quire homeostasis or adaptive responses to be exceeded.
However, in this particular case, the issue of dosimetry
and kinetics is given preference to the possible myriads
of ‘molecular events’ initiating and controlling the
changes in the pool-size and associated cellular and/or
inflammatory processes. Hence, the approach taken for
setting OELs utilizes the concept that the ‘cumulative
pulmonary dose’ from a modeled repeated inhalation
study on rats precedes the Point of Departure (POD) for
secondary adverse outcomes to occur.
Dissolution and bioavailability
No doubt, dissolution is tightly linked to the reciprocal re-
lationship of particle size and surface area which deter-
mines the thermodynamic phase boundary, where the
physical and chemical properties of the adjacent phases
change abruptly. As in any chemical reaction, surface pro-
cesses involve breaking and making of bonds. This is what
catalysis is all about. Mere reversible physical adsorption
may occur; however, the adsorbent may immediately be
lost by desorption, in the presence of substances with
competing or stronger binding isotherms. Hence, the term
‘surface area-/reactivity-dependence’ often preferred by
toxicologists, is a highly dynamic process depending both
on the kinetic and thermodynamic of factors present in
the intimate microenvironment of the particle as well as
of the physical and chemical properties of the particle
itself. Hence, from a modeling perspective, many surface-
related factors are highly probe-of-determination depen-
dent. The characteristics of the probes used for the
physicochemical qualification of PSP may not have any re-
semblance to those present in the biological system. Like-
wise, many simplified calculations of surface area based
on idealized spherical structures cannot reliably mirror
the more complex tree-dimensional assembly of nano-
structures and associated void spaces.
Particle dissolution is dependent on the rate of solubi-
lization (in mass/time), the surface area of particle and its
crystallinity or lack thereof in the case of amorphous
solids. Critically, the dissolution rate may depend on the
presence of other factors that determine the degree of
undersaturation in the liquid solvent layer immediately ad-
jacent to the solid solute particle. The term “interfacialsolubility” was proposed to describe the average concen-
tration of the boundary layer involved in the dissolution
process of particles. Interfacial barrier models consider
interfacial transport rather than diffusion through the
layer. “Solubilization” is the kinetic process involving both
dissolution and precipitation, which occur at the same
time but in different ratios, and usually proceed by diffu-
sion. The disjoining pressure of small particles is greater
than that of large particles, so small particles have a higher
interfacial solubility. Due to their higher differential con-
centration, thinner diffusion layer, and increased surface
area, small particles dissolve faster than larger particles.
Accordingly, a thermodynamically more stable state is
attained when larger particles grow at the expense of
smaller particles. Thus, even if ‘particle disintegration’
would occur it would result in a thermodynamically insta-
ble conditions [25-29].
Dissolution is the process by which a solute forms a
solution in a solvent. The solute, in the case of solids,
has its crystalline structure disintegrated as separate
ions, atoms, and molecules form. The amount of solute
in a solution is not always determined by its thermo-
dynamic solubility, but may depend on kinetics of dissol-
ution (or precipitation). The solubilization kinetics, as
well as apparent solubility can be accelerated by com-
plexation, e.g. metal ion binding by peptides or proteins
present in the lung. Solubility is commonly expressed as
a concentration (e.g. mass of solute per kg of solvent).
The maximum equilibrium amount of solute that can
dissolve per amount of solvent is the solubility of that
solvent under a given condition. The advantage of ex-
pressing solubility in this manner is its simplicity, while
the disadvantage is that it can strongly depend on the
presence of other species in the specific microenvi-
ronment of the particle. Despite the advances of in vitro
dissolution in particle qualification, the in vivo bioavail-
ability of retained particles in the lung remains to be
difficult to judge by in vitro tests. The toxicological signifi-
cance of translocation and disintegration of agglomerated
particles commonly ignores the complex equilibria of
dissolution and precipitation processes that may occur
in highly compartmentalized biological systems. For
example, the solubility of any inhaled metal oxides
mechanically translocated from the airways into the
gastrointestinal tract may show their highest solubility
in gastric fluids - due to low pH - with resultant high
concentration and mucosa-to-blood gradients as the
prerequisite for transport across barriers and absorp-
tion. With increasing pH following absorption, super-
saturated concentrations with precipitation may ensue.
Such precipitates may eventually be retrieved in the
liver and spleen. Thus, caution is advised to inextricably
link particles found in the extrapulmonary circulation
or organs to pulmonary barrier disruption.
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pear to be poorly suited to predict the bioavailability and
impact on fate with regard to dissolution in the lung. In
this context it is crucial to know whether the determined
in vitro values characterizing ‘solubility’ or ‘dissolution’
represent a thermodynamic equilibrium solubility or
whether they represent the values associated with a
metastable condition more suggestive of a kinetic equi-
librium. For more details on the distinction between
thermodynamic and kinetic equilibrium solubility, and
how one can exceed the equilibrium solubility to yield a
supersaturated solution, specialized literature should be
consulted [28-30]. If equilibrium is not reached, a false
impression on solubility is created, leading to inaccuracy
when comparing different particles. Thus, as can readily
be perceived, dissolution occurs up to the saturated con-
centration. In case the amount of bulk material used in
the assay to attain saturation is markedly increased, solu-
bility would become less (solubilized mass relative to the
mass of bulk material).
Mathematical models for the dissolution of solid parti-
cles involve accounting for the complicated changes in
the surface area and/or shape which occur during dissol-
ution. Solid particles in liquids can be modeled using
Nernst-Brunner type kinetics which is an extension of





SA  CS−Cð Þ
where M is the mass of solid material at a given time t,
SA is the area available for mass transfer, D is the diffu-
sion coefficient of the dissolving material, Vm is the dis-
solution medium volume, h is the diffusion boundary
layer thickness, C is the concentration, and Cs is the
substances saturation solubility. Diffusion-controlled
models were further refined for single spherical particle
dissolution under sink conditions and pseudo steady-
state of the kinetic release of a particles homogeneously
dispersed in a matrix into a medium under perfect sink
conditions [30]. However, given the assumptions used
to derive these models, the prediction may not be valid
over the entire range of the dissolution curves due to
the marked change of solid particle properties with de-
creasing size due to dissolution. Similarly, polydisperse
particle sizes and coated particles retained in an inflam-
matory milieu of the lung may add another dimension
of complexity to any model. Due to the longer life-time
of humans, time- and dissolution-related changes in
particle properties is biased to underestimate the con-
tribution of clearance by slow dissolution.
These elaborations demonstrate that any meaningful
in vivo dissolution kinetics should use inhalation instead
of instillation, insufflation or aspiration procedures todefine the fate of PSP. Likewise, to make the kinetic cor-
nerstones comparable across different substances, any
dissolution kinetics should refer to the cumulative lung
burdens within a meaningful range of the threshold of
kinetic overload. However, as PSP may unexpectedly be
more soluble in the lung than anticipated by alternative
methods, pre-studies with well-rationalized cumulative
lung burdens need to be executed as conceptualized in
Figure 1. Typically, the dominating pathway of elimination
of PSP from the lung occurs via alveolar macrophages
[14-20]. At yet non-overload conditions elimination half-
times of PSP retained in the lung are in the range of t1/2 =
60 to 90 days [4]. In case evidence of facilitated or en-
hanced dissolution of PSP exists a shortened half-time is
observed. Once the overload-condition is attained, this is
indicated by half-times exceeding t1/2 ~ 90 days (Figure 1).
An appropriately designed and executed 1- to 4-week re-
peated inhalation study can serve the purpose to verify
that the PSP under consideration can truly be regarded as
typical PSP under in vivo conditions.
The example shown in Figure 2 compares two sub-
stances commonly categorized as PSP, one is a chelate of
zinc (solubility in the range of ≤1 mg/L H2O), the other
was zinc oxide (ZnO, pigment grade; solubility in the
range of ~10 mg/L H2O) using a 7-day 6 h/day inhal-
ation bioassay on rats [31,32]. The mass median aero-
dynamic diameter (MMAD) and geometric standard
deviation (GSD) were for the chelate ~1.9 μm (2.3) and
for ZnO ~1.6 μm (1.6), respectively. The molar concen-
trations of Zn were essentially identical at 25 mg/m3
chelate and 7 mg/m3 ZnO. Empirically determined lung
burdens of Zn, assisted by kinetic modeling, yielded
elimination half-times of t1/2 = 3 and 0.8 days for the
chelate and ZnO, respectively. Sub-compartmental kin-
etics in BAL-cells yielded appreciably different cellular
doses of Zn. The chelate showed evidence of uptake by
alveolar macrophages (AM) whereas the dissolution of
ZnO seemed to be faster than the cellular uptake. The
elimination kinetics of BAL-cells mirrored that of the
total lung. Two weeks postexposure, all groups were in-
distinguishable from the air-exposed control. Surfactant
phospholipids and neutrophils (PMN) in BAL were max-
imally increased following exposure to ZnO with fast
clearance and reversibility of findings. A slightly slower
reversibility with a shallower time course occurred in
rats exposed to the chelate. Collectively, these relation-
ships show that both particles often considered to be
PSP-like dissolve rapidly in the lung. However, the dis-
solution rate of the chelate was slower than that of ZnO.
This confers time for the chelate to be endocytosed by
AM with protracted leaching from this cell. In turn,
micron-sized ZnO seemed to be instantly dissolved in
the alveolar lining fluids and cleared from the lung.
Other authors found that both mass and surface area
Figure 2 Schematic representation outlining the interrelationship of inhaled dose and kinetics, the ensuing effect, and the
sub-compartments of the lung were these dose-effect relationships are believed to occur for poorly soluble particles (Zn-chelate) at
1, 5, and 25 mg/m3 and less soluble particles (ZnO) at 7 mg/m3 (the last two concentrations were adjusted to attain equivalent molar
concentrations of Zn). Rats were exposed for 6 hours/day on seven consecutive days. Zn was determined in lung tissue and bronchoalveolar
(BAL) cells on postexposure days 1, 3, and 15. The findings presented demonstrate that solubility may affect the compartment were dissolution
and toxicity occurs. The highest toxicity occurred in ZnO-exposed rats at lower concentration of total dust (for more details see ref. [32]), which
delineates the importance of dissolution rate and flux (for details see [31,32]).
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Figure 1 Modeling of a 4-week repeated inhalation study in rats with minimally and/or poorly soluble particle at minimal overload
conditions. The simulations illustrate that ‘dissolution’ can readily be detected and quantified during post-exposure periods of 90-days but may
remain undetected during the actual exposure period. Elimination half-times (t1/2) of 80 and 120 days suggest normal to beginning overload-
related clearance, respectively. Half-times shorter than 60-days demonstrate a dissolution rate that might not necessarily be compatible with the
PSP paradigm.
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ticles (NPs) [33,34]. Hence, additional published evidence
supports the concept that the particle-size-dependence of
dissolution of extra- and/or intra-cellularly released zinc
ions may play a key role of mediating the toxicity of suffi-
ciently soluble particles. Therefore, the types of studies
shown in Figures 1 and 2 may serve as robust basis to dif-
ferentiate dissolution-related and substance-specific or
typical PSP-related outcomes.
Principles of particokinetics and -toxicity
Kinetic modeling provides a means to interrelate the cu-
mulative lung dose and study outcomes. These are be-
lieved to depend on two basic MoAs: (i) the MoAI-is
believed to convey a particle-specific acute adversity
whereas (ii) the MoAII is attributed to endocytosed PSP
following then the imposed kinetic of the phagocyte
(Figure 3). Hence, from an inherent toxicity perspective,
particles are expected to interact first with the lining
fluids or components thereof at the site of initial depos-
ition. The processes potentially involved have been con-
sidered in the preceding section. MoAI is destined toFigure 3 The dependent variables ‘elimination half-time’ (top left) an
relative to the independent variable ‘cumulative dose’ expressed as C
day this metric is proportional to the accumulated volumetric lung b
normal range of elimination half-times of t1/2 = 60 – 90 days which preced
(MTD) was believed to be attained at t1/2 = 1 year (vertical arrow right). For an
met at exposure concentrations of 0.06 μL PSPresp/m3 (NOAEL) and 0.26 PSPre
are expected to be t1/2 = 80 and 400 days, respectively. Of note is the increasi
burdens at MTD: a ~4-fold difference in exposure concentrations yielded a ~1impose acute effects caused by surfactant dysfunction ei-
ther related to PSP-specific effects or adsorption phenom-
ena [4,23]. Nonetheless acute-on-chronic aggravations
cannot be ruled out following recurrent exposures. How-
ever, due to the rapid re-synthesis of acutely depleted sur-
factant [35], such effect-related half-times are transitional
(1-3 days) relative to those mediated by MoAII [36].
Unlike humans, rats appear to be more susceptible to
the cumulative retention of inhaled PSP and associated
pulmonary inflammation because overload-related kin-
etic effects occur more readily due to their smaller pool-
volume of alveolar macrophages relative to humans
[4,15-18,37]. With regard to PSP-related inhalation haz-
ard characterization, missing models are a major stum-
bling block for providing definite regulatory guidance.
Within this framework, limited guidance is given as to
how ‘administered dose and dose-rate’ and/or ‘the cu-
mulative dose’ need to be adjusted not to exceed the
maximal tolerated dose (MTD) in repeated exposure
studies. The physiological clearance is deemed to be
exhausted at the MTD defined as elimination half-time
of t1/2 = 1 year (Figure 3) [4]. Based on the analysis givend ‘influx of neutrophils (PMN) in BAL’ (bottom left) were analyzed
respirable × Σt and both (in using an inhaled volume per exposure
urden; for details see reference [4]). The illustration supports a
es any influx of PMN (vertical arrow left). The maximum tolerated dose
y chronic 2-year inhalation study on rats these targeted cornerstones are
sp/m
3 (MTD). At these cumulative lung burdens the elimination half-times
ng disparity of external exposure concentrations and cumulative lung
7-fold higher lung burden at MTD (right) (for more details see [4]).
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half-time and increase of the pool of alveolar macro-
phages and polymorphonuclear neutrophils (PMN) can
be expected. Notably, this NOAEL to MTD relationship
matches a calculated volumetric lung burden of 1 to
10 μl PSP/lung. A similar relationship of a yet adaptive
to an exhausted displacement volume within the pool of
macrophage from 60 μm3 PSP/macrophage (6%) to
600 μm3 PSP/macrophage (60%) was postulated by Mor-
row [15,16]. Hence, despite the differing approaches
used to estimate the transition from homeostasis to
overload by Morrow [15] and Pauluhn [4] both concepts
present a unifying hypothesis in defining an overload-
dependent NOAEL and MTD. These concepts support
the notion that the intricate physiological system of the
rodents’ lung can totally be “overwhelmed” by extreme
lung burdens of PSP which may deteriorate unspecifi-
cally the intricate structure and function of the lung.
This calls for studies designs that utilize kinetically mod-
eled exposure regimens to prevent excessive, and toxico-
logically irrelevant cumulative lung burden beyond the
MTD to occur.
Another salt commonly presumed to be a PSP is
BaSO4 (solubility in water ~3 mg/L H2O [38]). Barium
sulfate was examined in rat inhalation studies as nano-
sized particles (41.4 m2 g−1; BET [39]) of 1-week (post-
exposure period 3 weeks) [40] and as fine particles
(3.1 m2 g−1; calculated) in a study of 17 and 29 weeksBaSO4
Stud




















Figure 4 Modeling of two C × Σt-adjusted subchronic barium sulfate
from Cullen et al. [9,32]. Symbols were reproduced from figures given by
t1/2 ≤ 60 days as well as the fact that the equal C × Σt of the longer expos
period suggest enhanced dissolution of particles. Fitted curves represent a
given in Figure 1, data had to be fit to the accumulation rather than the d
of analysis; however, elucidate further the intricate relationship of dissolutiofollowed by postexposure periods of 3 months [41]. The
MMAD and GSD were ~1.5 μm (2.1) and 4.3 (1.7), re-
spectively. Following exposure to the nano-sized parti-
cles 70% of the lung burdens were cleared within a
postexposure period of 3 weeks whereas the fine parti-
cles were eliminated at least twice as fast as would be
expected by macrophage mediated clearance (Figure 4).
The respective maximum lung burdens were about 12
mg BaSO4/lung and 6 mg BaSO4/lung [41,42]. These
studies were tolerated without any evidence of pulmon-
ary toxicity despite increased solubility and 10-fold dif-
ferences in particle surface areas. This outcome supports
the notion that in vitro “insolubility” in water cannot
readily be translated to that present in the pulmonary
system.Interdependence of metrics on dose
In the classical overload model, sixty percent of the
available pool volume of phagocytes (Vd) was considered
to be equal to the maximum theoretical ‘volume of dis-
tribution’ of retained PSP is the lung [15]. The tenth of
this fraction is considered to be the maximum yet
homeostatic Vd. For comparisons across species it was
assumed that these fractions do not change with cellular
size. The devised one-compartmental approach is a con-
servative simplification because lymphatic drainage and
dissolution are neglected. However, due to the longery Day
50 200 250 300
37.5 mg/m³ x 203d (5x7h/d); 5.5%
75 mg/m³ x 119 d (5x7h/d); 5.5%
37.5 mg/m³ - t1/2 = 50d
75 mg/m³ - t1/2 = 35d
inhalation studies with different particle size and surface areas
these authors. The elimination half-time of BaSO4 in the lung of
ure period produced half the lung burden of the shorter exposure
1st-order kinetics (for details see [4]). Opposite to the recommendation
ata lean elimination phase. This circumstance decreased the precision
n at possibly saturated conditions and MoAII-related clearance.
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conducive to non-negligible interstitial/lymphatic add-
itional clearance [43]. Significant translocation of PSP into
draining lymph nodes requires lung burdens high enough
to cause overload-related inflammation [4]. Hence, kinetic-
ally modeled NOAELs are considered to be sufficiently
conservative when using a one-compartmental concept
with the trade-off that lung burdens at increasing overload-
conditions are biased to be over-estimated due to the negli-
gence of interstitial clearance. Thus, the model devised is
implicitly over-conservative but considered to be more ro-
bust as it prevents any over-parameterization as often dic-
tated by multi-compartmental approaches. Based on the
data from diverse particle inhalation exposure studies on
rats (Figure 3) as well as the deliberations of other experts
[14,18-20] a 6% volumetric overload threshold within the
pool of alveolar phagocytes was used for defining the tran-
sition from adaptation to adversity.
Following the logic depicted in Figure 5, the NOAEL of
any study can be estimated to be 4.2 μl PSPresp/kg-rat as
detailed elsewhere [4]. The corresponding NOAEL to
MTD equivalent pooled volume of phagocytes then be-
comes 4.2 and 42 μl PSPresp/kg-rat, respectively. Assuming
unit density, mass-based, this overload-range equals 4.2-
42 mg/kg-rat PSP/kg-rat. On the level of a rat macrophage
this available volume is about 70-700 μm3/cell. Cell
cultures doses are often normalized to 106 cells. Under
in vitro conditions this threshold translates to a cellular
dose of 0.07-0.7 109 μm3/106 cells. With 1 μl = 109 μm3
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Figure 5 Dependence of the exposure regimen on the predicted volu
of 4.2 μL/kgrat (dashed horizontal line; for details see [4]). For each of
NOAEL in case MoAI-related findings do not increase at a higher ‘C’ and sh
to attain overload under any given condition is used to calculate the accum
(MoAII) NOAEL (see Figure 7).in inhalation studies a similar dose-range commonly is de-
livered over 28 or 90 days, in instillation or cellular bioas-
says this cumulative dose is administered as single bolus.
These cursory estimations show that many straightforward
instillation and in vitro cell-based studies may utilize a
dose-range beyond the volumetric threshold. This means,
MoAII-related outcomes become readily be saturated or
overwhelmed. Accordingly, such types of study design can
hardly reveal any volume-dependent etiopathology and a
surface area/activity-dependent metrics of toxicity can be
anticipated [36].
As exemplified in Figures 3 and 6, the dynamic increase
in elimination half-time causes (in rats) a disproportionality
of the external exposure concentration and the resultant
cumulative lung burden especially following chronic inhal-
ation. The actual exposure concentration (C) × Σexposure
days (Σt) relationship needs to be constructed in a way to
minimize MoAI-related effects relative to the MoAII-related
effects. For risk characterization, the most predictive C ×
Σt-relationship is that reflecting the chronic occupational
exposure regimen most, i.e., MoAI-related should essen-
tially be absent at the low and intermediate levels of expos-
ure. The predominating MoA is highly dependent on the
protocol executed. High-dose short-term and low-dose
long-term exposure regimens are biased to be dominated
by MoAI and MoAII, respectively (Figure 7) [36].
Deposition-related metric (MoAI)
It is frequently conceived that the conceptually better al-
ternative to particle mass as a measure of dose would bedy Day
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0.083*x))
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0.105 l/day - 13-wks
µ
µ
metric cumulative PSP volume at the kinetic overload threshold
the shown C × Σt –relationships, this threshold is anticipated to be the
orter ‘t’ [36]. The ratio of this PSP volume to the respective dose rate
ulation factor fv (insert) to estimate the generic retention-related
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Figure 6 Modeling of the accumulated volumetric lung burdens of rats exposed to respirable MWCNT (Baytubes) for 13 weeks [23].
The deposition (MoAI)-dependent “effect-related kinetics” was placed into perspective relative to the retention(MoAII)-related kinetics following a
post-exposure period of 6 months (for further details see [36]).
Pauluhn Particle and Fibre Toxicology  (2014) 11:72 Page 9 of 14the PSP-surface thermodynamics [7]. Surface area rather
than mass accounts for the fact that biopersistent parti-
cles can interact only by contact of their surface, deter-
mining an effective dose-rate by a catalytic surface
reaction rate that accumulates to an effective dose with
increasing residence time in the target tissue [44]. How-
ever, a finite proportion of soluble fractions of particles
that may dissolve on contact with the fluids lining the
airways of the lung - and so do not contribute to ‘surface
area dose’ (apart from the fact of surface area-dependentFigure 7 Predicted retention-related NOAELs (MoAII-based) of respira
to 1 year (for further details see [4,36]).facilitated dissolution [33]). Especially for less soluble
particles in a Cs-range 1 to 10 mg/L water, the dissol-
ution flux is not only highly dependent on the physical
characteristics of the particle itself, also the degree of
saturation of the matrix surrounding the particle has
great impact as already discussed above (Figures 1, 2 and
4). Along with these concerns, issues regarding the most
appropriate unifying metric of dose are still unresolved
for potentially soluble particles [45] which dissolution
rates increase reciprocally with PSP-size.ble ultrafine (UF)/pigmentary (P)-TiO2 at exposure durations up
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Independent of specialized subpopulations of AM, several
major variables have to be accounted for as a common re-
sponse to any increased endocytosis of endogenous (e.g.,
precipitated or denatured surfactant, pulmonary phos-
pholipidosis, and cellular debris) and exogenous poorly
soluble materials. These variables include hypertrophy
(enlargement commonly caused by excessive amounts
of phospholipids) of the AM with minimal, if any, increase
of the pool of macrophages. To the contrary, an increase
of the AM pool in the absence of any hypertrophy of cells
is the most common response observed in inhalation
studies with PSP [4,22]). At unequivocal overload coexist-
ence of both may occur. Typically (in rats), at yet reason-
able dose rates used in repeated inhalation toxicity
studies, the pool volume of AM adapts to higher PSP load
by the increased influx of cells rather than their enlarge-
ment [4,22,23].
Modeling of the homeostatic threshold
The NOAEL of any study can readily be calculated using
the 1-compartmental first-order kinetics depicted in
Figure 5. A more simplified practical approach for calcu-
lating this kinetic NOAEL is given in Figure 7. The basis
of this approximation is the following: the relative
weight of the exsanguinated lung to body weight in rats
from subchronic nose-only inhalation studies is 0.4 and
0.5% for male and female rats (Wistar-based), respect-
ively. The first term in the equation shown in Figure 7
defines the volumetric overload threshold dose per ex-
posure day normalized to kg-rat which was calculated to
be 4.2 × μL phagocyte-pool volume/kgrat [4] per ~4.5 g
lung/kgrat which is rounded to ~1 μL AM-pool volume/
lung inhaling 0.29 m3/kgrat per 6-hour exposure day [4].
Opposite to the extrapulmonary organs dosed by perfu-
sion, lung burdens have to be linked to body-weight-
adjusted ventilation and respirability of particles. In
order to retain this link, lung burdens were expressed
‘total lung-based’ relative to the body-weight-adjusted
ventilation. fv = -0.08 + 60.6 (1-exp(-0.083x)) is the frac-
tional volumetric daily exposure dose required to attain
steady state as given in Figure 5 (insert). This mathemat-
ical relationship is based on an exposure regimen of
6 hour/day on 5 consecutive exposure days/week. As
can be deduced from Figure 7, findings from short-term
high-dose studies are biased towards MoAI-related out-
comes with surface area/activity as lead metric whereas
long(er)-term studies are better suited of minimizing the
relative contribution of the MoAI (Figure 6), ideally sup-
ported by physiology-based kinetic modeling [36].
Simulated study design and verification of prediction
The wealth of data from biopersistent, low-toxicity PSP
repeated exposure inhalation studies on rats support acommon toxic principle [4]. Due to the low toxicity of
typical PSP, the comparison of many of these studies is
often hampered by differences in study design, lack of
lung burden analyses and fate, unexpected solubility,
and post-exposure periods shorter than the macrophage
mediated half-time of 60 days. The study design depicted
in Figure 8 attempts to minimize these types of data
gaps by demonstrating the coherence of the kinetically
predicted and empirically verified cumulative lung dose
with any integrated pulmonary effect. Based on the de-
tails given in Figures 5, 6 and 7, the lung burden-related
cornerstones of any repeated inhalation study can be
simulated (for details see [4]). The key study is then re-
stricted to a fully simulated study embracing the NOAEL
to the MTD and a kinetically calculated post-exposure
period suitable to demonstrate full reversibility at the
intermediate dose with no reversibility at the high-level
dose (1st step in Figure 8). Such a study is commonly
preceded by a validating, exploratory 1-week study for
technical optimization and validation. Few animals ex-
posed at this exposure level serve the purpose to validate
the analytical determination of lung burdens observing
post-exposure periods long enough to detect retention
half-times shorter than t1/2 = 60 days. In case this criter-
ion is fulfilled, the substance under consideration may
require additional qualification tests.
For a proven PSP, the targeted cornerstones of study
can be modeled in a 4-week OECD#412 [8,9] compliant
inhalation study using volumetric concentrations of 0.25,
0.75, and 2.2 μl PSPresp/m
3. The respirable fraction of
PSP (PSPresp) is that defined by OECD-GD#39 (2009).
The predicted elimination half-times are to be expected
in the range of 92, 148, and 292 days, respectively. Con-
fidence limits are not given to these point estimates due
to the numerous methodological variables affecting ‘in-
haled and retained dose’. Therefore, these and other esti-
mates from simulations need to be put into context with
the confidence intervals of the respective PODs from the
modeled and empirically verified repeated 4-week expos-
ure inhalation study. As exemplified elsewhere [23],
for entirely new and complex structures (Multi-walled
Carbon nanotubes) a modeled and empirically verified
13-week OECD#413 [8,10] seems to be the more appro-
priate and conservative approach. Mass concentrations
are calculated by multiplication of the apparent density
of PSP with the volume concentration. In case the em-
pirical outcome matches the prediction (Figure 8), the
NOAELs from longer study derations can then be pre-
dicted with reasonable accuracy [4,36]. In case an en-
tirely novel type of PSP with yet unknown toxicological
properties is tested, the same cycle using a 13-week ex-
posure period may be considered. The OEL can be de-
rived based on the calculated and experimentally verified
NOAEL using an assessment factor (AF) to adjust the
Figure 8 Kinetically simulated 4-week (left) and 13-week (right) OECD#412/413 [8-10] compliant inhalation studies on rats for
estimation of the volume concentration required to attain a cumulative PSP-volume lung burden similar to the NOAEL and the MTD.
Key is the selection of an intermediate concentration to demonstrate reversible lung-overload and associated adverse outcomes [4,36] within the
kinetically simulated post-exposure period. Simulations used volumetric concentrations of 0.25, 0.75, and 2.2 μl PSPresp/m3 for the 4-week study
and of 0.11, 0.3, and 1.0 μl PSPresp/m3 for the 13-week study. The simulations rely upon the correct estimate of that MPPD-modeled respirability
and agglomerate density achieved in the particular study under consideration (for details see [4,6,23]). Any faster reversibility than predicted
would have suggested facilitated dissolution of PSP in the lung. In case all constraints of the 4-week inhalation study are fulfilled, the NOAEL and
OEL/DNEL from longer exposure periods can be predicted. Adjustments for exposure durations (AF) have been detailed elsewhere [4,5]. Modelling
is not supported for substances where the predicted outcome of the 4-week study does not match the empirical outcome.
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ized in Figure 7. In the absence of kinetically designed
studies and empirically confirmed lung burdens and dos-
imetry substance-specific and retained-dose-related ef-
fects cannot be unequivocally differentiated [46].
Mechanisms, human relevance, and impact on risk
assessment
Employers are legally obliged to provide a working envir-
onment that does not endanger the health of employees
(e.g. Chemical Agent Directive 98/24/EC and Frame-
work Directive 89/391/EEC) [2,3]. Occupational expos-
ure limits (OELs) or Derived Human No-Effect Levels
(DNELs) are a useful instrument for the prevention of
health effects during the handling and use of chemicalsubstances [1]. OELs are defined as airborne concentra-
tions (expressed as time-weighted average for a conven-
tional 8-hour work day and a 40-hour work week) of a
substance to which it is believed that nearly all workers
may be repeatedly exposed (day after day, for a working
lifetime) without adverse effect. OELs are derived in con-
text with the registration and/or notification of chemicals.
Those derived by multi-expert groups (e.g., ACGIH, DFG,
SCOEL [47-49]) become legally binding workplace stan-
dards. Exposure concentrations are expressed in mg/m3.
Dosimetry adjustments across species of particles de-
posited in the various regions of the respiratory tract
and especially the alveoli require critical mode of action
(MoA)-based (dynamic) and kinetic information inter-
relating dynamics with biopersistence (mediated by AM
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cause insoluble particles deposit, accumulate and clear,
inter alia, along the surface of the lower respiratory
tract, normalization factors may differ from one MoA
and accumulating compartment to another [12]. Pub-
lished evidence suggests that the adaptively increase in
the pooled volume of alveolar phagocytes (Vd) matches
the increased payload of lung burdens best (MoAII) [4].
The NOAEL from kinetically modeled and experimen-
tally verified rat repeated inhalation studies (Figure 8) is
considered to be the POD for OEL-derivation in the ab-
sence of additional species-specific susceptibility factors
[7]. Notably, based on the concept to prevent ‘kinetic
overload’ and associated inflammation, the volume-
based generic mass concentration of 0.54 μl PSPresp × ρ/
m3 (ρ = apparent density of the PSP accumulated in the
phagocyte) appears to be scientifically justified and de-
fensible as a generic OEL for preventing PSP-induced
pulmonary overload-like conditions to occur in chronic-
ally exposed workers [4-6].
Mammalian species have developed finely-tuned lungs
adapted to their size and physiological needs. These must
be operational from a 25 g mouse with 300 breaths/
minute to a 70 kg human with 15 breaths/minute. The
basic structures involving PSP clearance and surfactant
homeostasis, have remarkable consistency across species
[35]. As can be expected, complex physiological relation-
ships exist between alveolar size and surface forces and
the way they coexist to maintain alveoli in a stable config-
uration. This interrelationship follows from the Laplace
relation (intra-alveolar pressure = 2 × surface tension/al-
veolar radius) showing that alveolar stability requires that
smaller alveoli of smaller mammalian species have more
functional surfactant than larger alveoli [50]. This intricate
balance is further complicated because smaller lungs and
airways to not allow for large reservoirs accommodating
surfactant and, if out of tune, mucus-like substances might
compromise lung function by the plugging small airways.
This particular configuration makes the lung of small la-
boratory rodents ultimately susceptible to high doses of
solid materials capable to adsorb and/or deteriorate pul-
monary surfactant.
Many mechanisms readily operative in humans to buf-
fer away such mechanical stimuli may not be feasible in
rodents. These types of MoAI-related etiopathologies
need to be thoughtfully characterized and put into hu-
man perspective for a balanced risk characterization. It
has been shown that the alveolar macrophage from
humans is larger than that from rats [51]. In addition,
also the total number of alveolar macrophages in the
lungs of humans is reported to be higher in humans as
compared to rats [4,21,52]. This circumstance makes
humans about 7-times more resistant to attaining lung
overload-like conditions than rats. Keeping in mind thatthe area patrolled by each AM can change dramatically
from one species to another, e.g, rat with 140,000 μm2/
AM vs. human 22,000 μm2/AM [52] humans seem to be
capable to keep their lung surface clean with a 7-fold
higher capacity as compared to rats which is entirely co-
herent with pool volume-based estimate of species dif-
ferences. Likewise, it is also important to recall that the
alveolar region of the rat and human has a lining fluid
(LF) volume of 26.4 and 8900 μl, respectively [53]. Ac-
counting for a pulmonary surface area of 0.34 m2 [54]
and 54 m2 [55] this then results in 78 and 165 μl LF/m2
for rats and humans, respectively. These considerations
support the concept that there is a much higher intrinsic
susceptibility of lungs of rats’ as compared to humans.
At occupational settings this type of portal-of-entry re-
lated toxicity (as a result of particle overload) is independ-
ent on any local metabolism. It also appears, as if the
cornerstones of particle clearance appear to be well
conserved in mammalian species and do not call for any
specific rat-to-human adjustments [35]. Therefore, these
bioassay-specific ‘implicit adjustment factors’ advocate to
focus on dosimetric species differences only (inhaled vol-
ume per exposure day, respirability of particles, and differ-
ences in elimination kinetics) as already conceptualized
elsewhere [4]. Related to mass concentrations any OEL of
any proven typical PSP can readily be calculated by multi-
plication of the volume concentration with the PM-
agglomerate density (ρ): OEL or DNEL [mg/m3] = 0.54 μl
PMresp/m
3 × ρ; ρ = 1 g/cm3). Interestingly, the conclusions
of this paper match almost exactly the deliberations of in-
dependent, multi-disciplinary expert groups engaged with
the derivation of legally binding occupational exposure
metric and limits of PSP (DFG-MAK Commission, Com-
mittee on Hazardous Substances): MAKDFG [mg/m
3] =
0.3 μl PMresp/m
3 × ρ [56,57], TRGS900-value = 0.5 μl
PMresp/m
3 × ρ [58] (both limits adjusted to mass/m3 using
an apparent density of ρ = 1g/cm3). Thus, similar to the
approach described in this paper, also the general dust
limit value considers the overload-dependent PSP-volume
metric to be superior to any elusive surface area related
metric as already suggested previously [3,36]. As typical
for these types of values, uncertainty is considered by
implicit assessment factors rather than any statistically
derived confidence limits [12].
Summary and conclusions
This treatise demonstrates that essentially two independ-
ent modes of action may act in concert in PSP-related
pulmonary toxicity. These are dependent on the cumula-
tive dose and regimen chosen to characterize hazards of
PSP. Due to its link to chronic workplace exposure,
MoAII retention-related effects are considered to be
amongst the key event leading to overload-dependent
pulmonary inflammation which occurrence must be
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week inhalation studies on rats (Figure 8) any presumed
PSP can unequivocally be classified as typical or non-
typical PSP in terms of dissolution kinetic and AM-
mediated clearance kinetic or any other yet unaccounted
toxicity. Accumulated empirical evidence from chronic
inhalation studies with true PSP yielded NOAELs similar
to the PSP-specific NOAEL or the predicted generic
NOAEL [4,6]. However, caution is advised in using these
paradigms for novel types of PSPs with unusual surface
thermodynamics and chemistry, complex kinetics of dis-
solution and/or yet uncharacterized PSP-specific toxicity.
Hypothesis-based kinetically-designed repeated inhal-
ation studies with fewer animals will minimize resource
consuming inhalation studies with outcomes determined
by PSP-specific rather than overload-related unspecific
effects. This provides a solid basis for a better com-
parison of PSPs with different characteristics as well as
prediction of safe occupational exposure levels in the
future.
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